{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:30:19Z","timestamp":1776274219979,"version":"3.50.1"},"reference-count":40,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: To characterize the prevalence of latent tuberculosis infection (LTBI) in patients with interstitial lung diseases (ILDs) requiring immunosuppression. Only 5 to 10% of individuals infected with Mycobacterium tuberculosis develop tuberculosis, and certain groups of patients have an increased risk of illness, such as the immunocompromised. Patients with ILDs are frequently treated with immunosuppressants and, therefore, might have a higher risk of developing the disease. Methods: Prospective study conducted at the ILD reference center of the Federal University of Paran\u00e1 from January 2019 to December 2020. The screening of LTBI was performed with the use of the tuberculin skin test (TST). Results: The sample consisted of 88 patients, of whom 64.8% were women, with a mean age of 61.4 years. The most frequent diagnoses were autoimmune rheumatic disease ILD (38.6%) and hypersensitivity pneumonitis (35.2%). The most common immunosuppressant in use at the time of the TST was prednisone, either in combination with mycophenolate (19.3%) or alone (17.1%). The majority of participants had fibrotic lung disease, characterized by a reticular interstitial pattern on chest computed tomography (79.5%) and moderate to severe functional impairment (mean FVC 69.2%). A prevalence of LTBI of 9.1% (CI 95%, 2.1%-15.1%) was found, with a TST median of 13. Conclusion: Patients with ILD who are treated with immunosuppressants are not commonly screened for LTBI, despite being under a greater risk of progression to active disease. This study suggests the need for a more cautious approach to these patients.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20210382","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T20:23:15Z","timestamp":1656015795000},"page":"e20210382","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression"],"prefix":"10.36416","author":[{"given":"Vitor","family":"Loureiro Dias1","sequence":"first","affiliation":[{"name":"1. Universidade Federal do Paran\u00e1, Curitiba (PR), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Mueller Storrer1","sequence":"additional","affiliation":[{"name":"1. Universidade Federal do Paran\u00e1, Curitiba (PR), Brasil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"ref0","unstructured":"REFERENCES"},{"key":"ref1","unstructured":"1.            World Health Organization \u2013 WHO. Global tuberculosis report 2020. Geneva: WHO; 2020. Report No.: 9789240013131."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"2.            Brasil. Minist\u00e9rio da Sa\u00fade. Brasil Livre da Tuberculose: Plano Nacional pelo Fim da Tuberculose como Problema de Sa\u00fade P\u00fablica. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2017. Report No.: 978-85-334-2496-8.","DOI":"10.1590\/s0102-311x2008000200019"},{"key":"ref3","unstructured":"3.            Brasil. Minist\u00e9rio da Sa\u00fade. Boletim Epidemiol\u00f3gico de Tuberculose. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2020."},{"key":"ref4","unstructured":"4.            Brasil. Minist\u00e9rio da Sa\u00fade. Boletim Epidemiol\u00f3gico de Tuberculose. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2021."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"5.            Brasil. Minist\u00e9rio da Sa\u00fade. Manual de Recomenda\u00e7\u00f5es para o Controle da Tuberculose no Brasil. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2018. Report No.: 978-85-334-2696-2.","DOI":"10.7476\/9788575416068.0002"},{"key":"ref6","unstructured":"6.            World Health Organization \u2013 WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: WHO; 2018."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"7.            Jee AS, Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs. 2019;79(14):1511-28. http:\/\/dx.doi.org\/10.1007\/s40265-019-01178-x. PMid:31399860.","DOI":"10.1007\/s40265-019-01178-x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"8.            Sociedade Brasileira de Pneumologia e Tisiologia. Diretrizes de Doen\u00e7as Pulmonares Intersticiais da Sociedade Brasileira de Pneumologia e Tisiologia. J Bras Pneumol. 2012;38(S2):S1-133.","DOI":"10.1590\/s1806-37132005000400013"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"9.            Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An Official American Thoracic Society\/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48. http:\/\/dx.doi.org\/10.1164\/rccm.201308-1483ST. PMid:24032382.","DOI":"10.1164\/rccm.201308-1483st"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"10.          Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976-87. http:\/\/dx.doi.org\/10.1183\/13993003.00150-2015. PMid:26160873.","DOI":"10.1183\/13993003.00150-2015"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"11.          Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis em adults. An Official ATS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36-69. http:\/\/dx.doi.org\/10.1164\/rccm.202005-2032ST. PMid:32706311.","DOI":"10.1164\/rccm.v203erratum1"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"12.          Kussen GM, Dalla-Costa LM, Rossoni A, Raboni SM. Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients em Brazil. Braz J Infect Dis. 2016;20(1):69-75. http:\/\/dx.doi.org\/10.1016\/j.bjid.2015.10.007. PMid:26706018.","DOI":"10.1016\/j.bjid.2015.10.007"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"13.          Vyas S, Thangakunam B, Gupta R, Michael JS, Christopher DJ. Interferon gamma release assay and tuberculin skin test positivity em sarcoidosis. Lung India. 2015;32(1):91-2. http:\/\/dx.doi.org\/10.4103\/0970-2113.148467. PMid:25624613.","DOI":"10.4103\/0970-2113.148467"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"14.          Jin Y, Wang H, Zhang J, Ding C, Wen K, Fan J, et al. Prevalence of latent tuberculosis infection among coal workers\u2019 pneumoconiosis patients em China: a cross-sectional study. BMC Public Health. 2018;18(1):473. http:\/\/dx.doi.org\/10.1186\/s12889-018-5373-1. PMid:29642880.","DOI":"10.1186\/s12889-018-5373-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"15.          Alipour Fayez E, Moosavi SAJ, Kouranifar S, Delbandi AA, Teimourian S, Khoshmirsafa M, et al. The effect of smoking on latent tuberculosis infection susceptibility em high risco individuals em Iran. J Immunoassay Immunochem. 2020;41(5):885-95. http:\/\/dx.doi.org\/10.1080\/15321819.2020.1806075. PMid:32799615.","DOI":"10.1080\/15321819.2020.1806075"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"16.          Ping PA, Zakaria R, Islam MA, Yaacob LH, Muhamad R, Wan Mohamad WMZ, et al. Prevalence and Risco Factors of Latent Tuberculosis Infection (LTBI) em Patients with Type 2 Diabetes Mellitus (T2DM). Int J Environ Res Public Health. 2021;18(1):305. http:\/\/dx.doi.org\/10.3390\/ijerph18010305. PMid:33406582.","DOI":"10.3390\/ijerph18010305"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"17.          Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127-35. http:\/\/dx.doi.org\/10.1056\/NEJMra1405427. PMid:26017823.","DOI":"10.1056\/nejmra1405427"},{"key":"ref18","unstructured":"18.          Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192-204. PMid:17131776."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"19.          Neema S, Radhakrishnan S, Dabbas D, Vasudevan B. Latent tuberculosis em psoriasis patients planned for systemic therapy \u2013 a prospective observational study. Indian Dermatol Online J. 2021;12(3):429-32. http:\/\/dx.doi.org\/10.4103\/idoj.IDOJ_698_20. PMid:34211910.","DOI":"10.4103\/idoj.idoj_698_20"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"20.          Silva DR, Rabahi MF, Sant\u2019Anna CC, Da Silva-Junior JLR, Capone D, Bombarda S, et al. Consenso sobre o diagn\u00f3stico da tuberculose da Sociedade Brasileira de Pneumologia e Tisiologia. J Bras Pneumol. 2021;47(2):e20210054.","DOI":"10.1590\/s1806-37132005000400013"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"21.          Hacioglu A, Borekci S, Melikoglu M, Ozguler Y, Esatoglu SN, Ugurlu S, et al. Screening for latent tuberculosis before starting TNF-alpha inhibitors em a population with high BCG vaccination rates. Rheumatol Int. In press, 2021. http:\/\/dx.doi.org\/10.1007\/s00296-021-04926-z. PMid:34228162.","DOI":"10.1007\/s00296-021-04926-z"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"22.          Hashash JG, Abou Fadel C, Hosni M, Hassoun L, Kanafani Z, Regueiro MD. Approach to latent tuberculosis infection screening before biologic therapy em IBD patients: PPD or IGRA? Inflamm Bowel Dis. 2020;26(9):1315-8. http:\/\/dx.doi.org\/10.1093\/ibd\/izaa139. PMid:32483628.","DOI":"10.1093\/ibd\/izaa139"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"23.          Ruan Q, Zhang S, Ai J, Shao L, Zhang W. Screening of latent tuberculosis infection by interferon-\u03b3 release assays em rheumatic patients: a systemic review and meta-analysis. Clin Rheumatol. 2016;35(2):417-25. http:\/\/dx.doi.org\/10.1007\/s10067-014-2817-6. PMid:25376466.","DOI":"10.1007\/s10067-014-2817-6"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"24.          B\u00e9lard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011;17(11):2340-9. http:\/\/dx.doi.org\/10.1002\/ibd.21605. PMid:21319275.","DOI":"10.1002\/ibd.21605"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"25.          Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis and positive tuberculin skin tests em a steroid-treated asthmatic population. Ann Intern Med. 1976;84(3):261-5. http:\/\/dx.doi.org\/10.7326\/0003-4819-84-3-261. PMid:1259260.","DOI":"10.7326\/0003-4819-84-3-261"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"26.          Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for latent tuberculosis em immunosuppressed patients at risco for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open. 2018;8(9):e022445. http:\/\/dx.doi.org\/10.1136\/bmjopen-2018-022445. PMID: 30209157.","DOI":"10.1136\/bmjopen-2018-022445"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"27.          Brasil. Minist\u00e9rio da Sa\u00fade. Relat\u00f3rio de recomenda\u00e7\u00e3o. Teste de libera\u00e7\u00e3o interferon-gama (interferon gamma release assay - IGRA) para detec\u00e7\u00e3o de tuberculose latente em pacientes imunocomprometidos. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2020.","DOI":"10.5123\/s1679-49742014000400009"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"28.          Shachor Y, Schindler D, Siegal A, Lieberman D, Mikulski Y, Bruderman I. Increased incidence of pulmonary tuberculosis em chronic interstitial lung disease. Thorax. 1989;44(2):151-3. http:\/\/dx.doi.org\/10.1136\/thx.44.2.151. PMid:2929001.","DOI":"10.1136\/thx.44.2.151"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"29.          Wong C, Sahni S, Cheema MAI, Iftikhar A. Mycobacterium tuberculosis Infection em the setting of interstitial lung disease: coincidence or bad luck? Cureus. 2018;10(10):e3391. PMid:30533326.","DOI":"10.7759\/cureus.3391"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"30.          Ehrlich R, Akugizibwe P, Siegfried N, Rees D. The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis. BMC Public Health. 2021;21(1):953. http:\/\/dx.doi.org\/10.1186\/s12889-021-10711-1. PMid:34016067.","DOI":"10.1186\/s12889-021-10711-1"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"31.          Vadillo Font C, Hern\u00e1ndez-Garc\u00eda C, Pato E, Morado IC, Salido M, J\u00fadez E, et al. Incidence and characteristics of tuberculosis in patients with autoimmune rheumatic diseases. Rev Clin Esp. 2003;203(4):178-82. http:\/\/dx.doi.org\/10.1016\/S0014-2565(03)71232-6. PMid:12681200.","DOI":"10.1016\/s0014-2565(03)71232-6"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"32.          Long W, Cai F, Wang X, Zheng N, Wu R. High risco of activation of latent tuberculosis infection em rheumatic disease patients. Infect Dis (Lond). 2020;52(2):80-6. http:\/\/dx.doi.org\/10.1080\/23744235.2019.1682187. PMid:31656117.","DOI":"10.1080\/23744235.2019.1682187"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"33.          Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risco of tuberculosis. Arthritis Rheum. 2006;55(1):19-26. http:\/\/dx.doi.org\/10.1002\/art.21705. PMid:16463407.","DOI":"10.1002\/art.21705"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"34.          Falagas ME, Voidonikola PT, Angelousi AG. Tuberculosis em patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents. 2007;30(6):477-86. http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2007.07.010. PMid:17913470.","DOI":"10.1016\/j.ijantimicag.2007.07.010"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"35.          Chiu YM, Chen DY. Infection risco em patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207-28. http:\/\/dx.doi.org\/10.1080\/1744666X.2019.1705785. PMid:31852268.","DOI":"10.1080\/1744666x.2019.1705785"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"36.          Fortes FML, Sorte NB, Mariano VD, Andrade LD, Oliveira FA, Santos MCA, et al. Active tuberculosis em inflammatory bowel disease patients under treatment from an endemic area em Latin America. World J Gastroenterol. 2020;26(44):6993-7004. http:\/\/dx.doi.org\/10.3748\/wjg.v26.i44.6993. PMid:33311945.","DOI":"10.3748\/wjg.v26.i44.6993"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"37.          Maciel MMMD, Ceccato MDG, Carvalho WDS, Navarro PD, Farah KP, Miranda SS. Prevalence of latent Mycobacterium tuberculosis infection in renal transplant recipients. J Bras Pneumol. 2018;44(6):461-8.  PMid:30726322.","DOI":"10.1590\/s1806-37562017000000367"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"38.          Anton C, Machado FD, Ramirez JMA, Bernardi RM, Palominos PE, Brenol CV, et al. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol. 2019;45(2):e20190023.  PMid:31038654.","DOI":"10.1590\/1806-3713\/e20190023"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"39.          Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy em rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol. 2008;20(4):443-9. http:\/\/dx.doi.org\/10.1097\/BOR.0b013e3283025ec2. PMid:18525359.","DOI":"10.1097\/bor.0b013e3283025ec2"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T20:23:20Z","timestamp":1656015800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jornaldepneumologia.com.br\/details\/3663\/en-US\/prevalencia-de-infeccao-latente-por-tuberculose-em-pacientes-com-doenca-pulmonar-intersticial-com-necessidade-de-imunossupressao"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":40,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20210382","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]}}}